[Expert consensus on the clinical application of anti-rabies virus monoclonal antibody (2025 edition)].

Abstract

The anti-rabies virus monoclonal antibody (RmAb) is a novel passive immunization for rabies developed and produced through modern genetic engineering technologies. It specifically binds to the antigenic sites on the G protein of the rabies virus surface, thereby blocking the virus from binding to cellular receptors and exerting a preventive effect. Compared to traditional rabies immunoglobulin, RmAb demonstrates superior advantages in terms of controllable production yield, stable quality, high safety profile, and favorable specific activity. Currently, four RmAb products have been approved for marketing worldwide. In response to the relatively limited understanding of RmAb among clinical practitioners, the Rabies Prevention and Control Committee of the Chinese Preventive Medicine Association and the Animal Injury Treatment Branch of China Association for Disaster and Emergency Rescue Medicine have organized domestic experts to compile this consensus. This document synthesizes the latest evidence, references relevant domestic and international standards, guidelines, and consensus statements, and incorporates expert clinical experience to provide scientific and standardized recommendations for clinical practice.

抗狂犬病病毒单克隆抗体（RmAb）是利用现代基因工程技术开发和生产的一种新型狂犬病被动免疫制剂，其可以特异性地与狂犬病病毒表面G蛋白上的抗原位点结合，阻断病毒与细胞表面受体的结合，从而起到预防作用。与传统的狂犬病免疫球蛋白相比，RmAb具有产量可控、质量稳定、安全性高、比活性好等优势。目前，全球已有4种 RmAb 产品获批上市。针对临床医生对RmAb认识相对不足的现状，中华预防医学会狂犬病预防控制工作委员会、中国医学救援协会动物伤害救治分会组织中国专家，收集最新证据，参考国内外相关规范、指南和共识，结合专家临床经验等，撰写本共识，为临床工作提供科学和规范的建议。.